How to buy AVROBIO stock | $5.58

AVROBIO Inc is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 121 staff and has a market cap (total outstanding shares value) of 0.00.

AVROBIO stock price (NASDAQ: AVRO)

Use our graph to track the performance of AVRO stocks over time.

AVROBIO shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$5.58
52-week range	$5.23 - $20.07
50-day moving average	$6.02
200-day moving average	$8.19
Wall St. target price	$23.44
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.10

Buy AVROBIO shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AVROBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVROBIO price performance over time

Historical closes compared with the close of $5.58 from 2021-10-20

1 week (2021-10-12)	-1.41%
1 month (2021-09-22)	-8.67%
3 months (2021-07-22)	-28.09%
6 months (2021-04-22)	-50.75%

1 year (2020-10-21)	-64.07%
2 years (2019-10-21)	-60.73%
3 years (2018-10-19)	27.44
5 years (2016-10-18)	N/A

AVROBIO financials

Gross profit TTM	$0
Return on assets TTM	-31.16%
Return on equity TTM	-53.47%
Profit margin	0%
Book value	$5.07
Market capitalisation	$253 million

TTM: trailing 12 months

Shorting AVROBIO shares

There are currently 2.3 million AVROBIO shares held short by investors – that's known as AVROBIO's "short interest". This figure is 32.8% down from 3.4 million last month.

There are a few different ways that this level of interest in shorting AVROBIO shares can be evaluated.

AVROBIO's "short interest ratio" (SIR)

AVROBIO's "short interest ratio" (SIR) is the quantity of AVROBIO shares currently shorted divided by the average quantity of AVROBIO shares traded daily (recently around 408267.44186047). AVROBIO's SIR currently stands at 5.59. In other words for every 100,000 AVROBIO shares traded daily on the market, roughly 5590 shares are currently held short.

However AVROBIO's short interest can also be evaluated against the total number of AVROBIO shares, or, against the total number of tradable AVROBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVROBIO's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 AVROBIO shares in existence, roughly 50 shares are currently held short) or 0.0703% of the tradable shares (for every 100,000 tradable AVROBIO shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AVROBIO.

Find out more about how you can short AVROBIO stock.

AVROBIO share dividends

We're not expecting AVROBIO to pay a dividend over the next 12 months.

AVROBIO share price volatility

Over the last 12 months, AVROBIO's shares have ranged in value from as little as $5.23 up to $20.07. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.3681. This would suggest that AVROBIO's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AVROBIO overview

AVROBIO, Inc. , a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of AVROBIO is owned by insiders or institutions?
Currently 2.939% of AVROBIO shares are held by insiders and 92.354% by institutions. How many people work for AVROBIO?
Latest data suggests 121 work at AVROBIO. When does the fiscal year end for AVROBIO?
AVROBIO's fiscal year ends in December. Where is AVROBIO based?
AVROBIO's address is: Building 300, Cambridge, MA, United States, 02139 What is AVROBIO's ISIN number?
AVROBIO's international securities identification number is: US05455M1009 What is AVROBIO's CUSIP number?
AVROBIO's Committee on Uniform Securities Identification Procedures number is: 05455M100